TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Thomas Fischer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.